8-K: Veradigm Inc. Faces Nasdaq Delisting, Continues Trading on OTC Expert Market

Veradigm Inc. will be delisted from the Nasdaq Stock Market following a Form 25 filing by Nasdaq, but its shares will continue to trade on the OTC Expert Market.

Summary

• Veradigm Inc. has been notified by Nasdaq that its securities will be delisted.
• This action follows the company's non-compliance with Nasdaq Listing Rules 5250(c)(1) and 5620(a).
• Trading of Veradigm's common stock on Nasdaq was suspended on February 29, 2024.
• Nasdaq filed a Form 25 with the SEC on April 25, 2024, to initiate the delisting process.
• The delisting will become effective ten days after the Form 25 filing.
• Veradigm's common stock has been trading on the OTC Expert Market under the symbol MDRX since the Nasdaq suspension.
• The company's preferred stock purchase rights are transferable only with the underlying common stock.
• The company anticipates that the Nasdaq delisting will not impact the trading of its securities on the OTC Expert Market.

Sentiment

Score: 4

Explanation: The sentiment is negative due to the delisting from Nasdaq, but the company's ability to continue trading on the OTC market mitigates some of the negative impact.

Positives

• The company's stock will continue to trade on the OTC Expert Market, ensuring investors can still trade the shares.
• Veradigm anticipates no practical impact on trading due to the delisting.

Negatives

• Veradigm has been delisted from Nasdaq due to non-compliance with listing rules.
• The company's stock was suspended from trading on Nasdaq on February 29, 2024.

Risks

• The delisting from Nasdaq could negatively impact investor confidence and the company's reputation.
• Trading on the OTC Expert Market may have lower liquidity and visibility compared to Nasdaq.

Future Outlook

The company expects that the final delisting action by Nasdaq will have no practical effect on the trading of its securities on the OTC Expert Market.

Management Comments

• The company expects that the final delisting action by Nasdaq will have no practical effect on the trading of its securities on the OTC Expert Market.

Industry Context

Delisting from a major exchange like Nasdaq can be a significant setback for a company, often leading to reduced investor confidence and potentially impacting its ability to raise capital. However, continued trading on the OTC market provides a venue for existing shareholders to trade their shares.

Comparison to Industry Standards

• Companies that fail to meet Nasdaq's listing requirements often face delisting, which is a common consequence of non-compliance.
• Trading on the OTC market is a typical alternative for companies delisted from major exchanges, although it generally involves lower trading volumes and less visibility.
• Other companies that have faced similar delisting situations include those with financial reporting issues or prolonged non-compliance with listing rules.

Stakeholder Impact

• Shareholders may experience reduced liquidity and visibility due to the move to the OTC Expert Market.
• The delisting could negatively impact investor confidence in the company.

Key Dates

Keywords

delisting, Nasdaq, OTC Expert Market, MDRX, non-compliance, Form 25, trading suspension, securities